EUVIMEDEUVIMED entdecken
Studienprotokoll

Faricimab in Previously Treated Neovascular Age-Related Macular Degeneration: Real-World Outcomes of a No-Loading-Dose Switching Protocol

Scott Lenhof, Thibaud Mathis, Nicolas Lepretre, Jonathan Rencker, Laurent Kodjikian

Ophthalmologica · 10.09.2026 · 1-1

DOI: 10.1159/oph/aeeag012 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Ophthalmologica, online erschienen am 10.09.2026. Verfasst von Scott Lenhof und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Department, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to evaluate the efficacy, anatomical outcomes, and safety of switching to faricimab without a loading dose, using a standardized institutional switch protocol, in patients with previously treated neovascular age-related macular degeneration (nAMD) who achieved a maximum fluid-free interval of 8 weeks or less with aflibercept or ranibizumab.

Methods

This retrospective, single-center cohort study was conducted at Croix-Rousse Hospital, Lyon and included eyes with a maximum fluid-free interval of 8 weeks or less on aflibercept or ranibizumab, switched to faricimab between November 2023 and December 2024. Eyes were classified as poor responders (PRs) or frequent flyers (FFs) based on their prior anti-vascular endothelial growth factor response. No loading dose was administered. The primary outcome was a change in the last intended treatment interval. Secondary outcomes included best-corrected visual acuity (BCVA), spectral-domain optical coherence tomography parameters, predictors of interval extension, and safety.

Results

128 eyes were included. Before switching, mean (standard deviation [SD]) treatment duration was 36.4 (21.9) months with a mean (SD) of 28.2 (17.0) intravitreal injections. After switching, the median gain in the last intended interval was 2.7 [IQR 2.1–3.3] weeks (p < 0.001). Subgroup analysis showed a median gain of 3.1 weeks in PRs (p < 0.001) and 2.4 weeks in FFs (p < 0.001). BCVA remained stable (p = 0.37). Significant reductions were observed in central macular thickness (p < 0.001), subretinal hyperreflective material (p = 0.02), intraretinal fluid (p < 0.001), and subretinal fluid (p < 0.001). Baseline characteristics were not associated with treatment interval extension. There was 1 case of anterior uveitis and vitritis, which resolved with topical corticosteroid treatment.

Conclusion

In previously treated nAMD patients, switching to faricimab without a loading dose achieved meaningful treatment interval extension, potentially reducing treatment burden without compromising efficacy.

Schlagwörter

Stichwörter der Autor:innen

Age-related macular degenerationFaricimabLoading-doseSwitchTreatment interval

Autor:innen und Institutionen

  • Ophthalmology Department, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France.
  • MATEIS Laboratory, UMR-CNRS 5510, INSA, University of Claude Bernard Lyon 1, Villeurbanne, France.
  • University of Claude Bernard Lyon 1, Lyon, France.
  • Ophthalmology Department, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France, laurent.kodjikian@chu-lyon.fr.
  • MATEIS Laboratory, UMR-CNRS 5510, INSA, University of Claude Bernard Lyon 1, Villeurbanne, France, laurent.kodjikian@chu-lyon.fr.
  • University of Claude Bernard Lyon 1, Lyon, France, laurent.kodjikian@chu-lyon.fr.

Zitieren

APA

Lenhof, S., Mathis, T., Lepretre, N., Rencker, J., & Kodjikian, L. (2026). Faricimab in Previously Treated Neovascular Age-Related Macular Degeneration: Real-World Outcomes of a No-Loading-Dose Switching Protocol. Ophthalmologica, 1-1. https://doi.org/10.1159/oph/aeeag012

Vancouver

Lenhof S, Mathis T, Lepretre N, Rencker J, Kodjikian L. Faricimab in Previously Treated Neovascular Age-Related Macular Degeneration: Real-World Outcomes of a No-Loading-Dose Switching Protocol. Ophthalmologica. 2026:1-1. doi:10.1159/oph/aeeag012

BibTeX
@article{Lenhof2026,
  author = {Lenhof, Scott and Mathis, Thibaud and Lepretre, Nicolas and Rencker, Jonathan and Kodjikian, Laurent},
  title = {Faricimab in Previously Treated Neovascular Age-Related Macular Degeneration: Real-World Outcomes of a No-Loading-Dose Switching Protocol},
  journal = {Ophthalmologica},
  year = {2026},
  pages = {1--1},
  doi = {10.1159/oph/aeeag012}
}
Kostenlos starten →